Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)’s stock price was up 5% on Friday . The stock traded as high as $10.27 and last traded at $10.26, approximately 104,300 shares were traded during trading. A decline of 39% from the average daily volume of 171,385 shares. The stock had previously closed at $9.77.
Several analysts have recently weighed in on EIGR shares. Wedbush restated an “outperform” rating and set a $35.00 price objective on shares of Eiger Biopharmaceuticals in a research report on Tuesday, June 18th. KeyCorp started coverage on shares of Eiger Biopharmaceuticals in a research report on Wednesday, June 26th. They set an “overweight” rating and a $10.72 price objective for the company. LADENBURG THALM/SH SH restated a “buy” rating and set a $28.00 price objective on shares of Eiger Biopharmaceuticals in a research report on Monday, August 12th. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, August 13th. Finally, ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $28.34.
The company has a current ratio of 9.64, a quick ratio of 8.16 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average price is $10.69 and its two-hundred day moving average price is $11.95.
A number of hedge funds have recently added to or reduced their stakes in EIGR. Bank of Montreal Can purchased a new stake in Eiger Biopharmaceuticals in the 2nd quarter valued at $28,000. Tower Research Capital LLC TRC raised its position in Eiger Biopharmaceuticals by 1,719.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,626 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Eiger Biopharmaceuticals in the 2nd quarter valued at $113,000. Jane Street Group LLC purchased a new stake in Eiger Biopharmaceuticals in the 4th quarter valued at $114,000. Finally, Wedbush Securities Inc. purchased a new stake in Eiger Biopharmaceuticals in the 1st quarter valued at $179,000. Hedge funds and other institutional investors own 80.68% of the company’s stock.
Eiger Biopharmaceuticals Company Profile (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.